Clinical trials: CMV Infection
HIV Infections, Cytomegalovirus Retinitis
Studies of the Ocular Complications of AIDS (SOCA)--Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT)
To evaluate the relative safety and efficacy of ganciclovir and foscarnet as initial treatment of patients with cytomegalovirus (CMV) retinitis.
- Trial name
- FGCRT (NCT00000136)
- Testing
- Foscarnet, Ganciclovir
- Volunteers
- 234 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Heart Transplantation, Cardiac Allograft Vasculopathy
Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy
Cardiac allograft vasculopathy (CAV) is the major cause of long-term graft failure in heart transplant recipients. Although several immune-mediated and metabolic risk factors have been implicated in the pathogenesis of CAV, no…
- Conditions
- Heart Transplantation, Cardiac Allograft Vasculopathy, Cytomegalovirus Infection
- Trial name
- PROTECT (NCT00966836)
- Testing
- Pre-emptive strategy with valganciclovir plus everolimus, Prophylaxis with valganciclovir plus mycophenolate, Prophylaxis with valganciclovir plus everolimus
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- University of Bologna
Cytomegalovirus Retinitis, HIV Infections
A Randomized, Controlled Study of the Safety and Preventive Efficacy of Oral Ganciclovir When Used in Conjunction With An Intravitreal Ganciclovir Implant in the Treatment of Cytomegalovirus Retinitis
To demonstrate the efficacy of oral ganciclovir in preventing new cytomegalovirus (CMV) disease in AIDS patients with unilateral CMV retinitis treated with an intravitreal ganciclovir implant.
- Trial name
- NCT00002134
- Testing
- Ganciclovir
- Where
- 23 sites in United States
- Volunteers
- 450 people
- Sponsor
- Roche Global Development
Pathogen Infection, EBV Infection
Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections
Epstein Barr Virus (EBV) or Cytomegalovirus (CMV) infection results in significant morbidity and mortality in hematopoietic stem cell transplantation (HSCT) patients.
- Conditions
- Pathogen Infection, EBV Infection, CMV Infection, Adenovirus Infection
- Trial name
- NCT03159364
- Testing
- pathogen-specific CTLs
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Cytomegalovirus Infections
A Study of Human Cytomegalovirus (HCMV) Vaccine SPYVLP01 With and Without Adjuvants
The main purpose of the study is to evaluate the safety and immunogenicity of SPYVLP01 in two different doses with and without adjuvants in healthy adults aged 18-50 years old.
- Trial name
- SPYVAC01 (NCT06145178)
- Testing
- SPYVAC01
- Where
- 2 sites in United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- SpyBiotech Limited
Cytomegalovirus Infections
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
This is a Phase II, randomized, double-blind, placebo-controlled study designed to assess the safety and clinical activity of multiple intravenous doses of MCMV5322A/MCMV3068A in cytomegalovirus (CMV)-seronegative recipients of a…
- Trial name
- NCT01753167
- Testing
- MCMV3068A, MCMV5322A
- Where
- 39 sites in United States, Belgium and 6 more
- Volunteers
- 122 people
- Sponsor
- Genentech, Inc.
Cytomegalovirus Infections, HIV Infections
The Safety and Effectiveness of FIAC in the Treatment of Cytomegalovirus (CMV) in Patients With AIDS
To find oral doses of FIAC (a pyrimidine nucleoside analog) that are effective in treating cytomegalovirus (CMV) viremia in HIV-infected immunocompromised patients; to determine tolerance and safety of FIAC in this patient…
- Trial name
- NCT00000981
- Testing
- Fiacitabine
- Where
- 4 sites in United States
- Volunteers
- 78 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Quantiferon-CMV, Cytomegalovirus Infections
Anti-CMV Cellular Immunity Quantification Using an IGRA Test in Kidney Transplant récipients and Hemodialysis Patients, Comparison to Control Patients
Evaluation of anti-CMV T cellular immunity using an IGRA test (Quantiferon-CMV test) in kidney transplant recipients and hemodialysis patients, comparison to control patients.
- Conditions
- Quantiferon-CMV, Cytomegalovirus Infections, Kidney Transplant Infection, Hemodialysis
- Trial name
- Quantiferon (NCT03916497)
- Testing
- Quantiferon CMV
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Grenoble
Adenovirus Infection, BK Virus Infection
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
This phase I trial tests the feasibility and safety of genetically modified cytotoxic T-lymphocytes in controlling infections caused by adenovirus (ADV), BK virus (BKV), cytomegalovirus (CMV), JC virus (JCV), or COVID-19 in…
- Conditions
- Adenovirus Infection, BK Virus Infection, Cytomegaloviral Infection, Hematopoietic and Lymphoid Cell Neoplasm
- Trial name
- NCT05101213
- Testing
- Virus-specific Cytotoxic T-lymphocytes
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
EBV Infection, CMV Infection
Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)
Subjects have a type of blood cell cancer, other blood disease or a genetic disease for which they received a stem cell transplant.
- Conditions
- EBV Infection, CMV Infection, Adenoviral Infection
- Trial name
- EAP CHALLAH (NCT01945619)
- Testing
- Trivirus-Specific CTLs
- Where
- 2 sites in United States
- Sponsor
- Baylor College of Medicine
Cytomegalovirus Retinitis, HIV Infections
A Study of Two Forms of Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS
To compare the time to progression of Cytomegalovirus (CMV) retinitis among each of three doses of oral ganciclovir, as well as to intravenous therapy, when given as maintenance for 26 weeks.
- Trial name
- NCT00002330
- Testing
- Ganciclovir
- Where
- 36 sites in United States, Canada
- Volunteers
- 280 people
- Sponsor
- Roche Global Development
Haematological Malignancies, CMV Infection
Study of Adoptive Immunotherapy With Donor-derived CMV-specific T Cells for Recipients of Allo-HSCT
The study will test the hypothesis that CMV TCR-transduced T cells, at a specific T-cell dose/kg, can generate a functional CMV immune response post-transplant, where CMV-specific donor T cells cannot be isolated by conventional…
- Trial name
- CMV_TCR-001 (NCT02988258)
- Testing
- CMV-TCR transduced donor-derived T cells
- Where
- 4 sites in United Kingdom
- Volunteers
- 10 people
- Sponsor
- University College, London
Cytomegalovirus Infection
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine
The main purpose of the extension phase of this study is to evaluate the longer-term immune persistence of mRNA-1647 vaccine administered to CMV-seronegative and CMV-seropositive adults who completed Study mRNA-1647-P202…
- Trial name
- NCT04975893
- Testing
- mRNA-1647
- Where
- 7 sites in United States
- Volunteers
- 135 people
- Sponsor
- ModernaTX, Inc.
Viral Pneumonia
PTH - Preemptive Treatment for Herpesviridae
The aim of this study is to show that a preemptive treatment by ganciclovir (for positive CMV viremia) or aciclovir (for positive HSV oro-pharyngeal PCR) is able to increase the number of ventilator-free days at Day 60.
- Trial name
- PTH (NCT02152358)
- Testing
- Aciclovir, Ganciclovir
- Where
- France
- Volunteers
- 317 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Cytomegalovirus Infections
Artesunate in Preemptive Treatment of Human Cytomegalovirus (CMV) in Stem Cell Transplant Recipients
Human cytomegalovirus (HCMV) has remained a major cause of morbidity and mortality following allogeneic bone marrow or peripheral blood stem cell transplantation (SCT).
- Trial name
- NCT00284687
- Testing
- Artesunate
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Hadassah Medical Organization
Cytomegalovirus Infections
Evaluation of the Pharmacokinetics (PK) and Pharmacodymamics (PD) of Ganciclovir (GCV) in Premature Infants Receiving Treatment for Cytomegalorivus (CMV) Infection
This is a clinical sampling study, and no study drugs will be administered under this protocol. Premature infants who receive intravenous ganciclovir as part of clinical care will be eligible for participation in this study.
- Trial name
- NCT01602614
- Where
- 15 sites in United States
- Volunteers
- 18 people
- Sponsor
- University of Alabama at Birmingham
Cytomegalovirus Infection
Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients
Cytomegalovirus (CMV) is a common cause of illness in patients who have undergone a transplant. Serious infections due to CMV can affect many parts of the body including the lungs, the gut, and the liver.
- Trial name
- NCT00817908
- Where
- Canada
- Volunteers
- 131 people
- Sponsor
- University of Alberta
Cytomegalovirus Infections, Solid Organ Transplantation Recipient
CMV Refractory and Resistant Infection in Solid Organ Transplant Recipients in Argentina
This study will describe the frequency and characteristics of refractory and resistant cytomegalovirus (CMV) infection in adults who received a solid organ transplant in Argentina between 2017 and 2024.
- Conditions
- Cytomegalovirus Infections, Solid Organ Transplantation Recipient, Solid Organ Transplantation
- Trial name
- NCT07787767
- Where
- Argentina
- Volunteers
- 200 people
- Sponsor
- Hospital Italiano de Buenos Aires
Ulcerative Colitis, Cytomegalovirus Infections
Prevalence of Cytomegalovirus Infection in Patients With Quiescent Ulcerative Colitis
Colitis from reactivation of established cytomegalovirus (CMV) colonization can complicate the clinical course in patients with an acute flare of ulcerative colitis (UC).
- Trial name
- PROVE-UC (NCT02684734)
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University of British Columbia
Hematopoietic Stem Cell Transplantation, Cytomegalovirus Infections
AntiCMV molécules Monitoring in Real-life in Stem Cell Recipients
Cytomegalovirus (CMV) is a ubiquitous herpesvirus that represent a major cause of morbidity in haematopoietic stem cell transplants (HSCT) recipients, mostly through reactivation of the recipient's virus.
- Conditions
- Hematopoietic Stem Cell Transplantation, Cytomegalovirus Infections, Antivirals, Antiviral Drug Resistance
- Trial name
- NAViRe (NCT04690933)
- Testing
- Real-life observatory of efficacy and resistance to anti CMV molecules in stem cell recipients
- Where
- 16 sites in France
- Volunteers
- 400 people
- Sponsor
- University Hospital, Limoges